A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits of Bevacizumab (Avastin) Treatment in Patients With Metastatic Breast Cancer (AVAREG Study)
Sponsor study identifier
observational
220
1 country
32
Study Start
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
March 2012
Actual (reported)Study Completion
March 2012
Actual (reported)This multicenter, single-arm observational study will evaluate the clinical benefits of Avastin (bevacizumab) in combination with paclitaxel in first-line treatment in patients with metastatic breast cancer. Patients with metastatic breast cancer who have started Avastin treatment within 6 months prior to study start will also be eligible. Data will be collected from patients for up to 5 years.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2012
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
March 2012
Actual (reported)March 2012
Actual (reported)January 24, 2013
Actual (reported)January 29, 2013
Actual (reported)February 5, 2016
Actual (reported)Progression Free Survival
Progression free survival (PFS) was assessed based on time to tumour progression or death (whichever occurred first) from the start of bevacizumab treatment.
Approximately 5 years
One Year Survival
Approximately 5 years
Time to Discontinuation (TTD) of Bevacizumab Treatment
Approximately 5 years
Participants With Hormone Receptor Status at Diagnosis
Baseline (Day 1)
Progression Free Survival in Participants With Triple Negative Receptor Status at Study Entry
Approximately 5 years
Participants With Tumor Stage at Diagnosis
Baseline (Day 1)
Patients with metastatic breast cancer initiated on treatment with Avastin in combination with paclitaxel
Budapest, 1031, Hungary
Budapest, 1076, Hungary
Budapest, 1082, Hungary
Budapest, 1088, Hungary
Budapest, 1097, Hungary
Budapest, 1106, Hungary
Budapest, 1115, Hungary
Budapest, 1122, Hungary
Clinical Trials
Hoffmann-La Roche
220 participants (actual enrollment reported by the registry).
First Submitted
January 24, 2013
First Posted
January 29, 2013
Study Start
December 2007
Date type not reportedThis date has not been verified as actual or estimated.
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
Contact the study team to confirm eligibility.
Budapest, 1125, Hungary
Budapest, 1135, Hungary
Budapest, 1145, Hungary
Debrecen, 4012, Hungary
Debrecen, H-4031, Hungary
Eger, 3300, Hungary
Győr, 9023, Hungary
Gyula, 5700, Hungary
Kaposvár, 7400, Hungary
Kecskemét, 6000, Hungary
Kistarcsa, 2143, Hungary
Miskolc, 3526, Hungary
Nyíregyháza, 4400, Hungary
Pécs, 7624, Hungary
Salgótarján, 3100, Hungary
Szeged, 6720, Hungary
Szekszárd, 7100, Hungary
Szentes, 6600, Hungary
Székesfehérvár, 8000, Hungary
Szolnok, 5004, Hungary
Szombathely, 9700, Hungary
Tatabánya, 2800, Hungary
Veszprém, 8200, Hungary
Zalaegerszeg, 8900, Hungary
Primary Completion
March 2012
Actual (reported)Study Completion
March 2012
Actual (reported)Last Updated
February 5, 2016
Results First Posted
February 5, 2016
Record last verified: 2016-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: